• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people.

作者信息

Hippisley-Cox Julia, Tan Pui San, Coupland Carol

机构信息

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.

出版信息

Heart. 2020 Nov 5. doi: 10.1136/heartjnl-2020-318312.

DOI:10.1136/heartjnl-2020-318312
PMID:33153994
Abstract
摘要

相似文献

1
Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people.使用血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂患重症2019冠状病毒病的风险：纳入830万人的队列研究。
Heart. 2020 Nov 5. doi: 10.1136/heartjnl-2020-318312.
2
Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people.ACE 抑制剂和血管紧张素受体阻滞剂与严重 COVID-19 疾病风险：包括 830 万人的队列研究。
Heart. 2020 Oct;106(19):1503-1511. doi: 10.1136/heartjnl-2020-317393. Epub 2020 Jul 31.
3
Mortality from angiotensin-converting enzyme-inhibitors and angiotensin receptor blockers in people infected with COVID-19: a cohort study of 3.7 million people.感染 COVID-19 的人群中血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂的死亡率：一项涉及 370 万人的队列研究。
Fam Pract. 2023 Mar 28;40(2):330-337. doi: 10.1093/fampra/cmac094.
4
Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients.抗高血压药物与 COVID-19 风险：一项涉及 200 万高血压患者的队列研究。
Hypertension. 2021 Mar 3;77(3):833-842. doi: 10.1161/HYPERTENSIONAHA.120.16314. Epub 2021 Jan 11.
5
Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With the Risk of Hospitalization and Death in Hypertensive Patients With COVID-19.血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂与 COVID-19 合并高血压患者住院和死亡风险的关系。
J Am Heart Assoc. 2021 Jul 6;10(13):e018086. doi: 10.1161/JAHA.120.018086. Epub 2021 Feb 24.
6
Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Blockers With Severity of COVID-19: A Multicenter, Prospective Study.血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂与 COVID-19 严重程度的关联：一项多中心前瞻性研究。
J Cardiovasc Pharmacol Ther. 2021 May;26(3):244-252. doi: 10.1177/1074248420976279. Epub 2020 Nov 24.
7
Inpatient Omission of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Is Associated With Morbidity and Mortality in Coronavirus Disease 2019.住院患者停用血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂与 2019 冠状病毒病的发病率和死亡率相关。
Clin Ther. 2021 Apr;43(4):e97-e110. doi: 10.1016/j.clinthera.2021.02.004. Epub 2021 Feb 25.
8
Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.血管紧张素 II 受体阻滞剂和 ACE（血管紧张素转换酶）抑制剂对 COVID-19 合并高血压患者病毒感染、炎症状态和临床结局的影响：一项单中心回顾性研究。
Hypertension. 2020 Jul;76(1):51-58. doi: 10.1161/HYPERTENSIONAHA.120.15143. Epub 2020 Apr 29.
9
Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers with the Risk of Hospitalization and Death in Hypertensive Patients with Coronavirus Disease-19.血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂与新型冠状病毒肺炎高血压患者住院和死亡风险的关联
medRxiv. 2020 May 19:2020.05.17.20104943. doi: 10.1101/2020.05.17.20104943.
10
Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial.在随机VATTC试验中血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂与预防角质形成细胞癌的关联
J Natl Cancer Inst. 2008 Sep 3;100(17):1223-32. doi: 10.1093/jnci/djn262. Epub 2008 Aug 26.

引用本文的文献

1
Use of drugs for hypertension or heart failure and the risk of death in COVID-19: association with loop-diuretics.使用降压药或心衰药与 COVID-19 患者死亡风险：与袢利尿剂相关。
Eur J Clin Pharmacol. 2024 Oct;80(10):1515-1522. doi: 10.1007/s00228-024-03709-2. Epub 2024 Jun 24.
2
Renin Angiotensin System and COVID-19 Infection.肾素-血管紧张素系统与新型冠状病毒肺炎感染
Adv Pharm Bull. 2022 Jan;12(1):1-4. doi: 10.34172/apb.2022.001. Epub 2021 Jan 23.
3
Angiotensin Converting Enzyme Inhibitors May Increase While Active Vitamin D May Decrease the Risk of Severe Pneumonia in SARS-CoV-2 Infected Patients with Chronic Kidney Disease on Maintenance Hemodialysis.
血管紧张素转换酶抑制剂可能会增加，而活性维生素D可能会降低接受维持性血液透析的慢性肾脏病患者感染新型冠状病毒肺炎后发生重症肺炎的风险。
Viruses. 2022 Feb 22;14(3):451. doi: 10.3390/v14030451.
4
Using primary care databases for addiction research: An introduction and overview of strengths and weaknesses.利用基层医疗数据库进行成瘾研究：优势与劣势介绍及概述
Addict Behav Rep. 2022 Jan 13;15:100407. doi: 10.1016/j.abrep.2022.100407. eCollection 2022 Jun.
5
Molecular mechanisms of the novel coronavirus SARS-CoV-2 and potential anti-COVID19 pharmacological targets since the outbreak of the pandemic.新型冠状病毒 SARS-CoV-2 的分子机制以及大流行爆发以来潜在的抗 COVID19 药理学靶点。
Food Chem Toxicol. 2020 Dec;146:111805. doi: 10.1016/j.fct.2020.111805. Epub 2020 Oct 8.